omniture
信达生物

Latest News

Innovent Out-Licenses Commercial Rights for Avastin® Biosimilar to Coherus BioSciences in the United States and Canada

SUZHOU, China, Jan. 14, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or the "Company")...

2020-01-14 08:00 2603

Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC

SUZHOU, China, Jan. 13, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a...

2020-01-13 12:42 5006

Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US

SUZHOU, China, Jan. 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...

2020-01-08 08:00 6689

Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting

SUZHOU, China, Dec. 10, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a...

2019-12-10 16:00 1003

Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-LAG-3 Monoclonal Antibody in China

SUZHOU, China, Dec. 6, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") ...

2019-12-06 08:00 9399

Innovent Presents Co-developed Cancer-Fighting Tyvyt(R) (Sintilimab Injection) at CIIE 2019 with Eli Lilly

SUZHOU, China, Nov. 28, 2019 /PRNewswire/ -- Innovent Biologics (01801.HK), a multinational biophar...

2019-12-02 09:37 3620

Tyvyt (Sintilimab Injection), an Innovative PD-1 Inhibitor Jointly Developed by Innovent and Lilly, is Included in the New Catalogue of National Reimbursement Drug List (NRDL)

SUZHOU, China, Nov. 28, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a...

2019-11-28 12:10 1271

Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-PD-1/HER2 Bispecific Antibody in China

SUZHOU, China, Nov. 27, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company")...

2019-11-27 07:50 772

Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma

SUZHOU, China, Oct. 21, 2019 /PRNewswire/ --  Innovent Biologics, Inc. ("Innovent" or "the Company"...

2019-10-21 08:00 616

Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

SUZHOU, China and LONDON, Oct. 10, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX...

2019-10-10 15:55 6051

Innovent Biologics Announces a New Placement Raised HK$2,351.33 Million

SUZHOU, China, Oct. 4, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") ...

2019-10-04 16:11 1187

Innovent Provides Update on Two Studies of IBI301 (Rituximab Biosimilar) in the Treatment of CD20-positive Lymphoma at Annual Meeting of CSCO

SUZHOU, China, Sept. 20, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a ...

2019-09-20 14:30 7199

Innovent Provides Update on the Results of IBI305 for the First-line Treatment of Advanced Non-squamous Cell Lung Cancer by Oral Presentation at CSCO

SUZHOU, China, Sept. 19, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a ...

2019-09-19 16:36 6966

Innovent Biologics Study Results of IBI303 in Patients with Ankylosing Spondylitis was Published in "The Lancet Rheumatology"

SUZHOU, China, Aug. 30, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a w...

2019-08-30 17:38 2607

Innovent Reports Interim Results for Fiscal Year 2019

SUZHOU, China, Aug. 29, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a w...

2019-08-29 08:39 1879

Innovent Enters a Licensing Agreement with Lilly to Develop & Commercialize a Novel Diabetes Medicine in China

SUZHOU, China, Aug. 22, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a w...

2019-08-22 07:30 1763

Innovent and Shenogen Announce Collaboration to Evaluate Tyvyt® (Sintilimab injection) in Combination with SNG1005 for the Treatment of Patients with Advanced Cancer

SUZHOU, China, Aug. 6, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a wo...

2019-08-06 08:00 1851

NMPA Accepts New Drug Application for IBI301, a Biosimilar Product Candidate of Rituximab (MabThera/Rituxan)

SUZHOU, China, June 27, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801) and ...

2019-06-27 12:21 9389
123